Showing 2601-2610 of 7669 results for "".
- And the Winners Are...Newsweek Names America’s Top Dermatologistshttps://practicaldermatology.com/news/and-the-winners-arenewsweek-names-americas-top-dermatologists/2461226/Newsweek has released the 2022 America‘s Best Dermatologists List in partnership with Statista. The list is split into two categories: cosmetic and medical and includes 275 dermatologists (125 cosmetic and 150 medical), many of whom sit on Practical Dermatology® and sister publication Modern Aesth…
- Cynosure Upgrades PicoSure System with PicoSure Pro Devicehttps://practicaldermatology.com/news/cynosure-upgrades-picosure-system-with-picosure-pro-device/2461220/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. An FDA-cleared 755nm picosecond laser, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide safe and effective treatments for …
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by data from two pivotal P…
- Timber's Topical Isotretinoin Gets Breakthrough Therapy Designation for CIhttps://practicaldermatology.com/news/timbers-topical-isotretinoin-gets-breakthrough-therapy-designation-for-ci/2461217/TMB-001, a topical isotretinoin formulated using patented IPEG™ delivery system from Timber Pharmaceuticals, Inc. has been granted Breakthrough Therapy designation by FDA for the treatment of congenital ichthyosis (CI). Timber is developing TMB-001 for the treatment of moderate to severe forms of …
- Verrica Receives Complete Response Letter from FDA for NDA for VP-102https://practicaldermatology.com/news/verrica-receives-complete-response-letter-from-fda-for-nda-for-vp-102/2461214/The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc.'s New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum). According to the company, the only deficiency listed in the CRL was related to the deficiencies identified at a…
- Lullage Launches in US on International Skin Pigmentation Dayhttps://practicaldermatology.com/news/lullage-launches-in-us-on-international-skin-pigmentation-day/2461213/Lullage, known as Bella Aurora in Europe and Asia, celebrates International Skin Pigmentation Day to raise awareness about the prevalence of skin pigmentation conditions and the methods available to help alleviate them. The day coincides with Lullage’s entry into the US market with its range of da…
- Global Dermatology Coalition Launcheshttps://practicaldermatology.com/news/global-dermatology-coalition-launches/2461212/The Global Dermatology Coalition, a patient-led, multi-stakeholder group of organizations, has launched during the 75th World Health Assembly in Geneva. The Global Dermatology Coalition includes dermatology patient organizations, health care professionals (dermatologists and dermatology nurses), re…
- Amytrx Therapeutics Raises $18M for New AD Treatmenthttps://practicaldermatology.com/news/amytrx-therapeutics-raises-18m-for-new-ad-treatment/2461211/Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research investigating AMTX-100, a new cell- penetrating immune system modulating peptide therapeutic for topical skin applications, specifically in atopic dermatitis and ot…
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We pride ourselves on being at the forefr…
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class. Dermavant says it will have product available in…